This paper presents a system-level method to decrease the power consumption of integrated audio Class-G amplifiers for mobile phones by using the same implementation of the level detector, but by changing the paramete...This paper presents a system-level method to decrease the power consumption of integrated audio Class-G amplifiers for mobile phones by using the same implementation of the level detector, but by changing the parameters of the switching algorithm. This method uses an optimization based on a simplified model simulation to quickly find the best power supply switching strategy in order to decrease the losses of the internal Class-AB amplifier. Using a few relevant equations of Class-G on the electrical level and by reducing the number of calculation points, this model can dramatically reduce the calculation time to allow power consumption evaluation in realistic case conditions compared to the currently available tools. This simplified model also evaluates the audio quality reproduction thanks to a psycho-acoustic method. The model has been validated by comparing model results and practical measurements on two industrial circuits. This proposed model is used by an optimizer based on a genetic algorithm associated with a pattern search algorithm to find the best power supply switching strategy for the internal Class-AB amplifier. The optimization results improve life-time performance by saving at least 25% in power consumption for typical use-case (1mW) compared to the industrial circuit studied and without losses in audio quality.展开更多
多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的血液系统恶性肿瘤,尽管新型蛋白酶体抑制剂、免疫调节剂及CD38单抗等药物的应用显著延长了患者的生存时间,但复发耐药仍难以避免。细胞免疫治疗,特别是嵌合抗原受体(chimeric antigen...多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的血液系统恶性肿瘤,尽管新型蛋白酶体抑制剂、免疫调节剂及CD38单抗等药物的应用显著延长了患者的生存时间,但复发耐药仍难以避免。细胞免疫治疗,特别是嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法的快速发展,极大程度的改变了复发/难治性(relapsed/refractory,R/R)MM患者的治疗现状。FDA目前已批准了2款靶向B细胞成熟抗原(B cell maturation antigen,BCMA)的CAR-T细胞产品,使其用于既往接受过4线及以上治疗的R/R MM患者。随着临床研究的不断深入,靶向GPRC5D(G protein-coupled receptor C class Group 5 member D,G蛋白偶联受体C类第5组成员D)的CAR-T细胞治疗也显示出其独特的优势。除了应用于难治复发的患者,多项临床试验支持CAR-T在MM中治疗线数的前移。本文就CAR-T细胞治疗在MM中开展的关键性临床研究展开综述,旨在为临床应用提供参考。展开更多
嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)的出现使得多发性骨髓瘤(multiple myeloma,MM)患者的治疗进入了一个新的阶段,但大多数患者都难逃原发耐药或疾病复发的不良结局。G蛋白偶联受体C类5组成员D(G protein-coup...嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)的出现使得多发性骨髓瘤(multiple myeloma,MM)患者的治疗进入了一个新的阶段,但大多数患者都难逃原发耐药或疾病复发的不良结局。G蛋白偶联受体C类5组成员D(G protein-coupled receptor class C group 5 member D,GPRC5D)是目前MM患者的一个有前景的治疗靶点,与GPRC5D CAR-T相关的Ⅰ期临床研究也都显示出较高的反应率和疗效。文章将对现有的靶向GPRC5D CAR-T细胞最新研究进行综述,旨在通过总结讨论目前不同GPRC5D CAR-T细胞治疗复发难治性MM的研究现状,对今后的临床治疗提供更多参考。展开更多
文摘This paper presents a system-level method to decrease the power consumption of integrated audio Class-G amplifiers for mobile phones by using the same implementation of the level detector, but by changing the parameters of the switching algorithm. This method uses an optimization based on a simplified model simulation to quickly find the best power supply switching strategy in order to decrease the losses of the internal Class-AB amplifier. Using a few relevant equations of Class-G on the electrical level and by reducing the number of calculation points, this model can dramatically reduce the calculation time to allow power consumption evaluation in realistic case conditions compared to the currently available tools. This simplified model also evaluates the audio quality reproduction thanks to a psycho-acoustic method. The model has been validated by comparing model results and practical measurements on two industrial circuits. This proposed model is used by an optimizer based on a genetic algorithm associated with a pattern search algorithm to find the best power supply switching strategy for the internal Class-AB amplifier. The optimization results improve life-time performance by saving at least 25% in power consumption for typical use-case (1mW) compared to the industrial circuit studied and without losses in audio quality.
文摘多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的血液系统恶性肿瘤,尽管新型蛋白酶体抑制剂、免疫调节剂及CD38单抗等药物的应用显著延长了患者的生存时间,但复发耐药仍难以避免。细胞免疫治疗,特别是嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法的快速发展,极大程度的改变了复发/难治性(relapsed/refractory,R/R)MM患者的治疗现状。FDA目前已批准了2款靶向B细胞成熟抗原(B cell maturation antigen,BCMA)的CAR-T细胞产品,使其用于既往接受过4线及以上治疗的R/R MM患者。随着临床研究的不断深入,靶向GPRC5D(G protein-coupled receptor C class Group 5 member D,G蛋白偶联受体C类第5组成员D)的CAR-T细胞治疗也显示出其独特的优势。除了应用于难治复发的患者,多项临床试验支持CAR-T在MM中治疗线数的前移。本文就CAR-T细胞治疗在MM中开展的关键性临床研究展开综述,旨在为临床应用提供参考。
文摘嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)的出现使得多发性骨髓瘤(multiple myeloma,MM)患者的治疗进入了一个新的阶段,但大多数患者都难逃原发耐药或疾病复发的不良结局。G蛋白偶联受体C类5组成员D(G protein-coupled receptor class C group 5 member D,GPRC5D)是目前MM患者的一个有前景的治疗靶点,与GPRC5D CAR-T相关的Ⅰ期临床研究也都显示出较高的反应率和疗效。文章将对现有的靶向GPRC5D CAR-T细胞最新研究进行综述,旨在通过总结讨论目前不同GPRC5D CAR-T细胞治疗复发难治性MM的研究现状,对今后的临床治疗提供更多参考。
